Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130024/S044

Lutonix 035 (Model 9004 and Model 9010)

Lutonix · Decision date Sep 4, 2025

FDA DECISIONP130024/S044

What did the FDA decide?

FDA records P130024/S044 as a supplement to PMA P130024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 4, 2025.

FDA approval order statement

reducing the frequency of residual solvent testing from every individual lot to a single lot per month
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 4, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P130024/S044
Regulatory pathway
PMA supplement
Applicant
Lutonix
Product code
ONU
Decision code
OK30
Decision date
Sep 4, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-Eluting Peripheral Transluminal Angioplasty Catheter.

Applicant
Lutonix
Product code
ONU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130024/S044 received

    Application receipt date recorded by FDA.

  2. P130024/S044 · FDA decision

    30-Day Notice

  3. P130024/S045 · Related supplement

    Lutonix 035 Drug Coated Balloon Catheter

Timeline entries are records held by MedtechLedger for P130024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130024

Product / regulatory recordCompanyPathwayDecision dateSource
LutonixPMA supplementJul 9, 2026FDA

Explore the linked device profile

Other records with product code ONU

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lutonix

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9409 Science Center Dr., New Hope, MN, 55428

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records